Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study
Authors:
- Seniha SenbayrakSSSeniha Senbayrak
- Nuri OzkutukNONuri Ozkutuk
- Hakan ErdemHEHakan Erdem
- Isik Somuncu JohansenIJIsik Somuncu Johansen
- Rok CivljakRok Civljak
- Ayse Seza InalAIAyse Seza Inal
- Uner KayabasUKUner Kayabas
- Ebru KursunEKEbru Kursun
- Nazif ElaldiNENazif Elaldi
- Branislava SavicBSBranislava Savic
- Soline SimeonSSSoline Simeon
- Emel YilmazEYEmel Yilmaz
Open Access
- 4 November 2015
- journal article
- research article
- Published by Springer Nature in Annals of Clinical Microbiology and Antimicrobials
- Vol. 14 (1) , 47
Abstract
Tuberculous meningitis (TBM) caused by Mycobacterium tuberculosis resistant to antituberculosis drugs is an increasingly common clinical problem. This study aimed to evaluate drug resistance profiles of TBM isolates in adult patients in nine European countries involving 32 centers to provide insight into the empiric treatment of TBM. Mycobacterium tuberculosis was cultured from the cerebrospinal fluid (CSF) of 142 patients and was tested for susceptibility to first-line antituberculosis drugs, streptomycin (SM), isoniazid (INH), rifampicin (RIF) and ethambutol (EMB). Twenty of 142 isolates (14.1 %) were resistant to at least one antituberculosis drug, and five (3.5 %) were resistant to at least INH and RIF, [multidrug resistant (MDR)]. The resistance rate was 12, 4.9, 4.2 and 3.5 % for INH, SM, EMB and RIF, respectively. The monoresistance rate was 6.3, 1.4 and 0.7 % for INH, SM and EMB respectively. There was no monoresistance to RIF. The mortality rate was 23.8 % in fully susceptible cases while it was 33.3 % for those exhibiting monoresistance to INH, and 40 % in cases with MDR-TBM. In compared to patients without resistance to any first-line drug, the relative risk of death for INH-monoresistance and MDR-TBM was 1.60 (95 % CI, 0.38–6.82) and 2.14 (95 % CI, 0:34–13:42), respectively. INH-resistance and MDR rates seemed not to be worrisome in our study. However, considering their adverse effects on treatment, rapid detection of resistance to at least INH and RIF would be most beneficial for designing anti-TB therapy. Still, empiric TBM treatment should be started immediately without waiting the drug susceptibility testing.Keywords
This publication has 21 references indexed in Scilit:
- Tuberculous meningitis: more questions, still too few answersThe Lancet Neurology, 2013
- A 43-year systematic review and meta-analysis: case-fatality and risk of death among adults with tuberculous meningitis in AfricaJournal of Neurology, 2013
- Influence of Antituberculosis Drug Resistance and Mycobacterium tuberculosis Lineage on Outcome in HIV-Associated Tuberculous MeningitisAntimicrobial Agents and Chemotherapy, 2012
- Molecular Profile of Drug Resistance in Tuberculous Meningitis From Southwest ChinaClinical Infectious Diseases, 2011
- War and infection in the pre-antibiotic era: The Third Ottoman Army in 1915Scandinavian Journal of Infectious Diseases, 2011
- Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort studyBMJ, 2010
- Mycobacterial infections2010
- Is HIV Infection a Risk Factor for Multi-Drug Resistant Tuberculosis? A Systematic ReviewPLOS ONE, 2009
- Effect of Antituberculosis Drug Resistance on Response to Treatment and Outcome in Adults with Tuberculous MeningitisThe Journal of Infectious Diseases, 2005
- Multidrug‐Resistant Tuberculous Meningitis in KwaZulu‐Natal, South AfricaClinical Infectious Diseases, 2004